Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.69 |
| ▸ | FAAH | O00519 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.56 |
| ▸ | F7 | P08709 | 3/20 | 0.56 |
| ▸ | F3 | P13726 | 3/20 | 0.56 |
| ▸ | PPARG | P37231 | 3/20 | 0.56 |
| ▸ | PPARD | Q03181 | 2/20 | 0.56 |
| ▸ | PPARA | Q07869 | 2/20 | 0.56 |
| ▸ | FABP3 | P05413 | 2/20 | 0.56 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.56 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.56 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.56 |
| ▸ | FABP4 | P15090 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1533680 | 1.00 | EPHX2 (0.69) | EPHX2FAAHALDH1A1KDM4EF7 | |
| SCHEMBL3458829 | 1.00 | EPHX2 (0.69) | EPHX2FAAHALDH1A1KDM4EF7 | |
| SCHEMBL2637146 | 1.00 | EPHX2 (0.69) | EPHX2FAAHALDH1A1KDM4EF7 | |
| SCHEMBL8985935 | 1.00 | EPHX2 (0.69) | EPHX2FAAHALDH1A1KDM4EF7 | |
| SCHEMBL8985933 | 1.00 | EPHX2 (0.69) | EPHX2FAAHALDH1A1KDM4EF7 | |
| SCHEMBL1259282 | 1.00 | EPHX2 (0.69) | EPHX2FAAHALDH1A1KDM4EF7 | |
| SCHEMBL11370740 | 0.94 | EPHX2 (0.75) | EPHX2FAAHF7F3PPARG | |
| SCHEMBL2219389 | 0.94 | EPHX2 (0.75) | EPHX2FAAHF7F3PPARG | |
| SCHEMBL8349583 | 0.94 | EPHX2 (0.75) | EPHX2FAAHF7F3PPARG | |
| SCHEMBL1962429 | 0.94 | EPHX2 (0.75) | EPHX2FAAHF7F3PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240316206-A1 | NOVEL LIPID FORMULATIONS FOR DELIVERY OF THERAPEUTIC AGENTS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-09-26 | — | — | US | disclosed |
| US-12016929-B2 | Lipid formulations for delivery of therapeutic agents | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-06-25 | — | — | US | disclosed |
| US-20240148875-A1 | NOVEL LIPID FORMULATIONS FOR DELIVERY OF THERAPEUTIC AGENTS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-05-09 | — | — | US | disclosed |
| US-20240100166-A1 | NOVEL LIPID FORMULATIONS FOR DELIVERY OF THERAPEUTIC AGENTS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-03-28 | — | — | US | disclosed |
| US-11786598-B2 | Lipid formulations for delivery of therapeutic agents | ARBUTUS BIOPHARMA CORPORATION (CA) | 2023-10-17 | — | — | US | disclosed |
| US-20230248831-A1 | NOVEL LIPID FORMULATIONS FOR DELIVERY OF THERAPEUTIC AGENTS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2023-08-10 | — | — | US | disclosed |
| US-11446383-B2 | Lipid formulations for delivery of therapeutic agents | ARBUTUS BIOPHARMA CORPORATION (CA) | 2022-09-20 | — | — | US | disclosed |
| US-20190240339-A1 | NOVEL LIPID FORMULATIONS FOR DELIVERY OF THERAPEUTIC AGENTS TO SOLID TUMORS | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2019-08-08 | — | — | US | disclosed |
| US-20190106379-A1 | NOVEL CYCLIC CATIONIC LIPIDS AND METHODS OF USE | ARBUTUS BIOPHARMA CORPORATION (CA) | 2019-04-11 | — | — | US | disclosed |
| US-10077232-B2 | Cyclic cationic lipids and methods of use | ARBUTUS BIOPHARMA CORPORATION (CA) | 2018-09-18 | — | — | US | disclosed |
| US-20130122104-A1 | NOVEL LIPID FORMULATIONS FOR DELIVERY OF THERAPEUTIC AGENTS TO SOLID TUMORS | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2013-05-16 | — | — | US | disclosed |
| US-20130123339-A1 | COMPOSITIONS AND METHODS FOR SILENCING APOLIPOPROTEIN B | PROTIVA BIOTHERAPEUTICS INC (CA) | 2013-05-16 | — | — | US | disclosed |
| US-20130116307-A1 | NOVEL CYCLIC CATIONIC LIPIDS AND METHODS OF USE | PROTIVA BIOTHERAPEUTICS INC. (CA) | 2013-05-09 | — | — | US | disclosed |
| US-8283333-B2 | Lipid formulations for nucleic acid delivery | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2012-10-09 | — | — | US | disclosed |
| US-20120202871-A1 | CATIONIC LIPIDS AND METHODS FOR THE DELIVERY OF THERAPEUTIC AGENTS | PROTIVA BIOTHERAPEUTICS, INC. | 2012-08-09 | — | — | US | disclosed |
| US-8236943-B2 | Compositions and methods for silencing apolipoprotein B | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2012-08-07 | — | — | US | disclosed |
| EP-2449106-A1 | COMPOSITIONS AND METHODS FOR SILENCING APOLIPOPROTEIN B | Protiva Biotherapeutics Inc. (CA) | 2012-05-09 | — | — | EP | disclosed |
| EP-2449114-A1 | NOVEL LIPID FORMULATIONS FOR DELIVERY OF THERAPEUTIC AGENTS TO SOLID TUMORS | Protiva Biotherapeutics Inc. (CA) | 2012-05-09 | — | — | EP | disclosed |
| WO-2011141703-A1 | COMPOSITIONS AND METHODS FOR SILENCING APOLIPOPROTEIN B | PROTIVA BIOTHERAPEUTICS INC. (CA) | 2011-11-17 | — | — | WO | disclosed |
| WO-2011141704-A1 | NOVEL CYCLIC CATIONIC LIPIDS AND METHODS OF USE | PROTIVA BIOTHERAPEUTICS, INC (CA) | 2011-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116307-A1 | NOVEL CYCLIC CATIONIC LIPIDS AND METHODS OF USE | LDLR, CETP, ABHD16A | EPHX2 3171/4885FAAH 3876/4885ALDH1A1 4770/4885 |
| US-20240100166-A1 | NOVEL LIPID FORMULATIONS FOR DELIVERY OF THERAPEUTIC AGENTS | PNLIP, NPC1L1, CETP | EPHX2 3146/4885FAAH 2156/4885ALDH1A1 2161/4885 |
| US-10077232-B2 | Cyclic cationic lipids and methods of use | CETP, LDLR, ABHD16A | EPHX2 3133/4885FAAH 3559/4885ALDH1A1 4771/4885 |
| US-20230248831-A1 | NOVEL LIPID FORMULATIONS FOR DELIVERY OF THERAPEUTIC AGENTS | PNLIP, NPC1L1, CETP | EPHX2 3146/4885FAAH 2156/4885ALDH1A1 2161/4885 |
| US-11446383-B2 | Lipid formulations for delivery of therapeutic agents | CETP, PNLIP, NPC1L1 | EPHX2 3019/4885FAAH 1966/4885ALDH1A1 1878/4885 |
| US-20240148875-A1 | NOVEL LIPID FORMULATIONS FOR DELIVERY OF THERAPEUTIC AGENTS | PNLIP, NPC1L1, CETP | EPHX2 3146/4885FAAH 2156/4885ALDH1A1 2161/4885 |
| US-20120202871-A1 | CATIONIC LIPIDS AND METHODS FOR THE DELIVERY OF THERAPEUTIC AGENTS | LDLR, NPC1, CETP | EPHX2 3165/4885FAAH 3631/4885ALDH1A1 4573/4885 |
| US-20190240339-A1 | NOVEL LIPID FORMULATIONS FOR DELIVERY OF THERAPEUTIC AGENTS TO SOLID TUMORS | PNLIP, CETP, NPC1L1 | EPHX2 3171/4885FAAH 1988/4885ALDH1A1 2057/4885 |
| US-20190106379-A1 | NOVEL CYCLIC CATIONIC LIPIDS AND METHODS OF USE | LDLR, CETP, ABHD16A | EPHX2 3171/4885FAAH 3876/4885ALDH1A1 4770/4885 |
| US-20130123339-A1 | COMPOSITIONS AND METHODS FOR SILENCING APOLIPOPROTEIN B | APOB, LDLR, APOL1 | EPHX2 2425/4885FAAH 2495/4885ALDH1A1 3439/4885 |
| US-20130122104-A1 | NOVEL LIPID FORMULATIONS FOR DELIVERY OF THERAPEUTIC AGENTS TO SOLID TUMORS | PNLIP, CETP, NPC1L1 | EPHX2 3171/4885FAAH 1988/4885ALDH1A1 2057/4885 |
| US-20240316206-A1 | NOVEL LIPID FORMULATIONS FOR DELIVERY OF THERAPEUTIC AGENTS | PNLIP, NPC1L1, CETP | EPHX2 3146/4885FAAH 2156/4885ALDH1A1 2161/4885 |
| US-11786598-B2 | Lipid formulations for delivery of therapeutic agents | CETP, PNLIP, NPC1L1 | EPHX2 3019/4885FAAH 1966/4885ALDH1A1 1878/4885 |
| US-12016929-B2 | Lipid formulations for delivery of therapeutic agents | CETP, PNLIP, NPC1L1 | EPHX2 3019/4885FAAH 1966/4885ALDH1A1 1878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.